Ellie Leick

Articles

Jagannath Shares Insight on Treatment Strategies in Relapsed/Refractory Myeloma

August 28th 2019

Sundar Jagannath, MD, highlights the current state of the relapsed/refractory multiple myeloma paradigm and research regarding next steps for advancing treatment.

Garon Recaps Long-Term Pembrolizumab Data in NSCLC, Lurbinectedin Activity in SCLC

August 27th 2019

Edward B. Garon, MD, MS, highlights the 5-year KEYNOTE-001 data and also the activity with lurbinectedin in small cell lung cancer.

ctDNA Testing Now Valuable Tool in CRC, Next Steps Underway

August 20th 2019

Pashtoon M. Kasi, MBBS, MD, MS, discusses the use of ctDNA testing throughout treatment for patients with colorectal cancer and ongoing research on liquid biopsies.

PARP Inhibition Continues to Make Waves in Ovarian Cancer

August 19th 2019

Terry L. Evans, MD, discusses the use of PARP inhibitors in ovarian cancer and how they are poised to optimally fit in the treatment paradigm.

Acalabrutinib Shows Benefit in Ibrutinib-Treated Relapsed/Refractory CLL

August 19th 2019

Kerry A. Rogers, MD, highlights the findings of a study examining acalabrutinib in ibrutinib-intolerant patients with relapsed/refractory chronic lymphocytic leukemia and the next steps for the data.

Pivotal Trials With CDK4/6, PI3K Inhibitors Propel Progress in HR+ Breast Cancer

August 15th 2019

Leticia Varella, MD, discusses the progression of available treatments in hormone receptor-positive, HER2-negative metastatic breast cancer.

Rugo Shares Insight on Intriguing SOPHIA Data in HER2+ Breast Cancer

August 14th 2019

Hope S. Rugo, MD, discusses the findings from the phase III SOPHIA trial and the potential impact of margetuximab on HER2-positive metastatic breast cancer.

Expert Explains Intricacies of Molecular Testing in Ovarian Cancer

August 13th 2019

Sarah E. Taylor, MD, discusses the role of somatic and germline testing for patients with ovarian cancer and their family members to create more personalized treatment and prevent disease.

Immunotherapy Transforms Frontline Stage IV Squamous NSCLC Treatment

August 12th 2019

Jennifer W. Carlisle, MD, highlights the research surrounding immunotherapy in frontline lung cancer treatment.

Neoadjuvant Chemo Shows Comparable Data to Upfront Surgery in Ovarian Cancer

August 8th 2019

Michelle M. Boisen, MD, discusses the role of neoadjuvant chemotherapy in advanced ovarian cancer and data comparing outcomes with this modality versus upfront surgery.

PACIFIC Immunotherapy Data Open Research Opportunities in Stage III NSCLC

August 7th 2019

Drew Moghanaki, MD, MPH, discusses the impact of the PACIFIC trial and future research in stage III non–small cell lung cancer.

Lurbinectedin Study Shows Single-Agent Potential in Second-Line Small Cell Lung Cancer

August 7th 2019

Anna F. Farago, MD, PhD, discusses the second-line data with lurbinectedin and its potential impact on the small cell lung cancer field.

IMpassion130 Trial Takes Immunotherapy to Forefront of TNBC

August 6th 2019

Eleni Andreopoulou, MD, discusses the impact of the IMpassion130 trial on TNBC treatment and the use of immunotherapy in this patient population.

Biomarkers May Indicate Eligibility for PARP Inhibitors in Lung Cancer

August 5th 2019

Jonathan Riess, MD, MS, discusses ongoing research with PARP inhibitors in lung cancer and potential biomarkers for this class of agents.

Genetic Variant Causes Susceptibility to TNBC in African Subpopulations

August 2nd 2019

Lisa Newman, MD, MPH, FACS, FASCO, highlights the history and ongoing research of the genotype causing predisposition to TNBC in African-American women.

Is Neoadjuvant Chemo Becoming Standard of Care for Advanced Ovarian Cancer?

August 2nd 2019

Mitchel Hoffman, MD, explains the use of surgery and neoadjuvant chemotherapy in ovarian cancer.

SOLO-1 Paves Path for Frontline Maintenance in Ovarian Cancer

August 1st 2019

Hye Sook Chon, MD, discusses the progress of maintenance therapy in ovarian cancer.

Window-of-Opportunity Strategies Continue to Make Headway in Lung Cancer

July 26th 2019

Paul A. Bunn Jr, MD, highlights the benefits of preoperative window-of-opportunity studies, specifically with immunotherapy in lung cancer.

Quadruplet Regimens Show Promising Activity in Multiple Myeloma

July 26th 2019

Ajai Chari, MD, discusses current and emerging research in patients with transplant-eligible and -ineligible multiple myeloma as well as updates in smoldering multiple myeloma.

Novel CAR T-Cell Approaches Emerging in Multiple Myeloma

July 25th 2019

Deepu Madduri, MD, discusses ongoing trials examining CAR T-cell therapy in myeloma and the potential to use it in earlier lines of therapy.